A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.
The consumer genomics firm says employer benefits programs could expand access to BRCA1/2, Lynch syndrome, and FH genetic testing in the general population.
Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.
The company plans to use proceeds to further invest in its development of molecular testing and other strategies in the preventive medicine space.
The latest offering puts the genetic testing company on the path toward becoming what it calls a preventive health service company.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
Based on evidence the company submitted on the test, and helped by its low pricing, Color also has preferred provider status with a number of plans.
The company, which has been offering its hereditary cancer risk test at a self-pay rate of around $250, will continue to work with insurers to grow in-network status.
With the $250 service, Color is hoping to broaden access to genetic testing and make it easier for researchers to incorporate genetics in their studies.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.